GLP - 3 RT 30mg [next - gen weight loss]

Overview
Retatrutide is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors — earning it the designation “GLP-3” for its triple-receptor mechanism. In Phase 2 clinical trials, Retatrutide produced the most significant weight loss results ever recorded for a pharmaceutical compound, with participants losing an average of 24% of their body weight over 48 weeks. It represents the cutting edge of metabolic and obesity research.

Mechanism of Action
Retatrutide’s triple-receptor mechanism creates a powerful and synergistic metabolic effect. GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion. GIP receptor activation enhances insulin sensitivity and supports fat metabolism. Glucagon receptor activation drives hepatic fat oxidation and increases energy expenditure. The combination of all three pathways produces a degree of fat loss and metabolic improvement that surpasses any single or dual-agonist compound.

Research Applications
Research on Retatrutide has focused on obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular risk reduction. Phase 2 trial data has demonstrated unprecedented reductions in body weight, visceral fat, liver fat content, and cardiometabolic risk markers. It is currently considered the most promising next-generation weight loss compound in clinical development.

Reconstitution & Storage
Retatrutide is supplied as a lyophilized powder. Reconstitute by adding bacteriostatic water slowly along the inner wall of the vial. Store unreconstituted vials away from direct light. Once reconstituted, keep refrigerated.

Download Dosing Guide 

Reconstitution Video